Description

trastuzumab-deruxtecan

Trastuzumab deruxtecan (Enhertu) is a treatment for breast cancer, advanced stomach cancer, non-small cell lung cancer, and solid tumors with HER2 gene mutations in certain patients. Trastuzumab deruxtecan may help people with cancer live longer and delay the progression of their disease.

The active ingredient, fam trastuzumab deruxtecan nxki, is commonly shortened to trastuzumab deruxtecan or T-DXd.

Trastuzumab deruxtecan combines targeted therapy and chemotherapy into one treatment, known as an antibody-drug conjugate (ADC). The targeted therapy part, fam-trastuzumab (T), recognizes and attaches to HER2-positive cancer cells to help block their ability to grow and multiply. Once attached, the chemotherapy component, deruxtecan (DXd), is released inside the cancer cells, destroying them.

HER2-Positive Breast Cancer:

• HER2-positive Stage II or III early breast cancer followed by a taxane, trastuzumab, and pertuzumab (THP) before surgery. Your healthcare provider will perform a test to make sure this medicine is right for you.
• HER2-positive breast cancer that cannot be removed by surgery or has metastasized, in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure this medicine is right for you.
• HER2-positive early breast cancer in patients who have received trastuzumab (with or without pertuzumab) and taxane-based treatment before surgery, and have cancer remaining in the tissue removed during surgery. Trastuzumab dextran is used as monotherapy.
• HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
  • for metastatic disease, or
  • have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
• HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received prior chemotherapy:
  • for metastatic disease, or
  • whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure this medicine is right for you.